The Department of RadiationOncology at Gachon University Gil Hospital recently signed a business agreementwith medical artificial intelligence (AI) startup ONCOSOFT to transfertechnology.
The 'radiotherapy dosegradient analysis method' developed by Professor Kihoon Sung of the Departmentof Radiation Oncology at Gachon University Gil Hospital is a technology thatcan minimize the side effects of high-dose radiation therapy by preciselyanalyzing the dose around the tumor, which has been overlooked in existingevaluation methods.
Prof. Kihoon Sung and his teamtransferred the technology to ONCOSOFT. Software incorporating Oncosoft'sspecialized AI technology will be developed. We plan to develop software thatestablishes a customized radiation treatment plan for patients based on AItechnology and introduce it to the clinical field.
Oncosoft is a company thatdevelops AI-based radiation cancer treatment software. Radiotherapy is atreatment that uses high doses of radiation to selectively kill cancer cellswhile maximizing the protection of surrounding normal tissue from radiation.
The treatment depends on thetype of cancer, the cancerous tissue, and the anatomical location of normalorgans. Since all human organs have different sensitivities to radiation,precise radiation treatment planning is required to minimize side effects duringtreatment. The main software required for this is ▲ contouring technology for normal organs inmedical images such as CT and MRI ▲ technology to predict the radiation dose for each cancerous tissue andorgan. OncoSoft has developed AI-based medical image automatic contouring SW'OncoStudio' and obtained a Class 2 medical device license from the Ministry ofFood and Drug Safety in February 2022.
"With this agreement, weexpect to support safe and precise patient-customized radiotherapy by providingreal-time radiotherapy planning with the advanced AI-based radiotherapyplanning SW that OncoSoft is developing," said Jinsung Kim, CEO ofOncoSoft.
"AI software innovationsfor precision radiotherapy planning are validated by hospitals," saidProf. Kihoon Sung, "and we look forward to introducing reliable precisionradiotherapy planning methods to the clinical field through thisagreement."
